Eclampsia pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 17: Line 17:


Placenta consists of two components:
Placenta consists of two components:
====[[Decidua]====
====[[Decidua]]====
====[[Chorionic Villi]]====
====[[Chorionic Villi]]====



Revision as of 11:40, 14 August 2021

https://https://www.youtube.com/watch?v=RB5s85xDshA%7C350}}

Eclampsia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Eclampsia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Eclampsia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eclampsia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eclampsia pathophysiology

CDC on Eclampsia pathophysiology

Eclampsia pathophysiology in the news

Blogs on Eclampsia pathophysiology

Directions to Hospitals Treating Eclampsia

Risk calculators and risk factors for Eclampsia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

While multiple theories have been proposed to explain preeclampsia and eclampsia, it occurs only in the presence of a placenta and is resolved by its removal.[1] E. W. Page suggested that placental hypoperfusion is a key feature of the process. It is accompanied by increased sensitivity of the maternal vasculature to pressure agents leading to vasospasm and hypoperfusion of multiple organs. Further, an activation of the coagulation cascade leads to microthombi formation and aggravates the perfusion problem. Loss of plasma from the vascular tree with the resulting edema additionally compromises the situation. These events lead to signs and symptoms of toxemia including hypertension, renal, pulmonary, and hepatic dysfunction, and - in eclampsia specifically - cerebral dysfunction.[1] Preclinical markers of the disease process are signs of increased platelet and endothelial activation.[1]

Pathophysiology

Anatomy and Physiology of placenta

The formation of the placenta commences with the development of trophoblast. After the fertilization of the ovum in the fallopian tubes, it travels towards the uterus and by the time it reaches the uterus it has already become a morula. The morula is still surrounded by the zona pellucida which prevents it from sticking to the walls of the tube. The zona pellucida disappears soon after the blastocyst reaches the uterine cavity. Now the cells lining the blastocyst constitute the trophoblast whose function is to invade the surrounding uterine tissues to provide nutrition to the developing blastocyst. When the trophoblast attaches to the endometrium, it is known as implantation, which begins on the sixth day after fertilization in humans. This process is additionally enhanced by the proteolytic enzymes produced by the trophoblast and the interaction between the receptors present uterine epithelium and L-selectin and integrins produced by the trophoblast cells. Hence, implantation is a result of mutual exchange between the endometrium of the uterine cavity and the trophoblastic cells surrounding the blastocyst.

Placenta consists of two components:

Decidua

Chorionic Villi

Pathophysiology

Placental hypoperfusion is linked to abnormal modeling of the fetal-maternal interface that may be immunologically mediated[1] The invasion of the trophoblast appears to be incomplete.[2] Adrenomedullin, a potent vasodilator, is produced in diminished quantities by the placenta in preeclampsia (and thus eclampsia).[3] Other vasoactive agents are at play including prostacyclin, thromboxane A2, nitric oxide, and endothelins leading to vasoconstriction.[4] Many studies have suggested the importance of a woman's immunological tolerance to her baby's father, whose genes are present in the young fetus and its placenta and which may pose a challenge to her immune system.[5]

Eclampsia is seen as form of a hypertensive encephalopathy in the context of those pathological events that lead to preeclampsia. It is thought that cerebral vascular resistance is reduced, leading to increased blood flow to the brain. In addition to abnormal function of the endothelium, this leads to cerebral edema.[6] Typically an eclamptic seizure will not lead to lasting brain damage; however, intracranial hemorrhage may occur.[7]

Histopathology

{{#ev:youtube|ZluEUwp1oD4}}

References

  1. 1.0 1.1 1.2 1.3 JM Roberts, DW Cooper. "Series, Pre-eclampsia trio. Pathogenesis and genetics of pre-eclampsia". The Lancet 2001; 357:53-56.
  2. Zhou Y, Fisher SJ, Janatpour M, Gembacev O, Dejana E, Wheelock M; et al. "Human cytotrophoblasts adopt a vascular phenotype as they differentiate: a strategy for successful endovascular invasion?". J Clin Invest 1997;99:2139-51.
  3. Hongshi L., Dakour J, Kauman S, Guilbert LJ, Winkler-Lowen B, Morrish DW. "Adrenomedullin is decreased in preeclampsia because of failed response to epidermal growth factor and impaired syncytialization". Hypertension 2003, vol. 42, no5, pp. 895-900.
  4. ACOG. "Diagnosis and Management of Preeclampsia and Eclampsia". ACOG Practice Bulletin # 33, 2002,.
  5. "Sex Primes Women for Sperm". BBC News. 2002-02-06. Text " http://news.bbc.co.uk/2/hi/health/1803978.stm" ignored (help); Check date values in: |date= (help); |access-date= requires |url= (help)
  6. Cipolla MJ (2007). "Cerebrovascular function in pregnancy and eclampsia". Hypertension. 50 (1): 14–24. doi:10.1161/HYPERTENSIONAHA.106.079442. PMID 17548723. Unknown parameter |month= ignored (help)
  7. Richards A, Graham D, Bullock R. "Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy". J Neurol Neurosurg Psychiatry 1988;51:416-21.

Template:WH Template:WS